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Abstract The binding of low density lipoprotein (LDL) to the
platelet cell membrane could facilitate the transfer of phospho-
lipids from LDL to the platelets. A polyclonal antibody against
the platelet glycoproteins IIb/IIIa inhibited the high affinity
binding of 125I-LDL by up to 80%. The transfer of pyrene (py)-
labeled sphingomyelin (SM), phosphatidylcholine and phospha-
tidylethanolamine from LDL to the platelets was unaffected by
the antibody. The lectin wheat germ agglutinin (WGA) reduced
the binding of 125I-LDL to the platelets by approximately 80%.
In contrast, the lectin stimulated the transfer of SM from LDL
into the platelets by about three-fold. WGA also specifically
augmented the transfer of py-SM between lipid vesicles and the
platelets, the stimulation being abolished in the presence of
N-acetylglucosamine. Dextran sulfate (DS) increased the
specific binding of 125I-LDL to the platelets by up to 2.8-fold.
On the other hand, the import of LDL-derived py-phospholipids
was unaffected by DS. Together, the results indicate that the
phospholipid transfer from LDL to the platelets is independent of
the high affinity LDL binding to the platelets and is specifically
stimulated by WGA. Thus, the interactions of platelets with
LDL phospholipids differ markedly from those with the
apoprotein components of the lipoproteins.
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1. Introduction
In recent years, de¢ned functions in intracellular signaling
events have been assigned to nearly all types of membrane
phospholipids. Furthermore, distinct phospholipids were
shown to interact with speci¢c proteins thereby regulating
cellular functions implicated in di¡erent physiological situa-
tions. For example, the exposure of phosphatidylserine at cel-
lular surfaces was shown to play a prominent role in coagu-
lation as well as in early apoptosis [1,2]. In view of these
essential functions of membrane phospholipids it appears ob-
vious that the composition and localization of phospholipids
in cellular membranes has to be tightly controlled. This is
accomplished by enzymes involved in the de novo synthesis
of phospholipids [3], by remodelling of the phospholipids (e.g.
due to the actions of acyltransferases and transacylases) at the
level of the membranes [4] and by proteins mediating the
transfer of phospholipids between the two halves of the bi-
layer [5,6].
We recently obtained evidence that an additional mecha-
nism might be relevant for the biogenesis of the platelet phos-
pholipid composition, namely the import of lipoprotein-de-
rived phospholipids [7^9]. The major phospholipids of low
and high density lipoproteins (LDL and HDL) (phosphatidyl-
choline (PC), sphingomyelin (SM) and phosphatidylethanol-
amine (PE)) were found to be rapidly transferred to the plate-
lets in an endocytosis-independent manner [7]. The uptake of
LDL-derived phospholipids was shown to contribute to sup-
plying platelets with arachidonic acid. The newly imported
phospholipid-bound arachidonic acid was shown to be metab-
olized subsequently to eicosanoids such as thromboxane A2
[8]. When platelets were activated by the agonists thrombin
and collagen, the incorporation of ethanolamine phospholip-
ids was speci¢cally stimulated [9]. This was apparently medi-
ated by proteins secreted from the platelets. The acceleration
of import of ethanolamine phospholipids enhanced the pro-
thrombinase activity of the platelets [9].
Platelets possess saturable binding sites for LDL particles
[10,11]. The platelet membrane glycoprotein (GP) IIb/IIIA
complex (integrin KIIbL3) was previously shown to be part
of the high a⁄nity binding sites for LDL particles [12]. Bind-
ing of LDL to their platelet receptors allows the lipoproteins
to physically interact with the platelet surface. We hypothe-
sized that this might facilitate the transfer of phospholipids
from the lipoproteins to the platelets. In order to test this
hypothesis, we evaluated whether agents that modulated spe-
ci¢c LDL binding to platelets a¡ected the transfer of phos-
pholipids from LDL to the platelets. In further experiments
we analyzed the potential involvement of LDL apoproteins in
the phospholipid transfer process.
2. Materials and methods
2.1. Materials
1-Palmitoyl-2-pyrenedecanoyl-sn-3-glycerophosphorylcholine (py-
PC), 1-palmitoyl-2-pyrenedecanoyl-sn-3-glycerophosphorylethanol-
amine (py-PE) and (N-pyrenedecanoyl)-sphingomyelin (py-SM) were
from Sigma (Deisenhofen, Germany) or from Molecular Probes (Eu-
gene, OR, USA). 1-Palmitoyl-2-[14C]arachidonoyl-sn-glycero-3-phos-
phorylcholine (14C-20:4-PC) and [N-methyl-14C]sphingomyelin (14C-
SM) were obtained from NEN DuPont (Homburg). Polyclonal anti-
bodies against GPIIb and GPIIIa were raised in rabbits by application
of a mixture of both glycoproteins [13]. The IgG fraction was isolated
by chromatography using protein A-Sepharose. Speci¢city was eval-
uated by Western blot techniques. Thereby, the antibody solution was
found to bind to GPIIb and GPIIIa up to dilutions of 1:4000. Ilo-
prost was kindly donated by Schering (Berlin, Germany). Pancreatic
elastase (type IV), apyrase, K1-antitrypsin, WGA and N-acetyl-D-glu-
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cosamine were from Sigma (Deisenhofen, Germany). Dextran sulfate
was from Pharmacia (Freiburg, Germany).
2.2. Preparation of platelets
Fresh venous blood was anticoagulated with acid-citrate-dextrose
(15 mM citric acid, 90 mM trisodium citrate, 16 mM Na2HPO4, 160
mM glucose, pH 5.0; 1 part anticoagulant to 6 parts blood). The
mixture was centrifuged for 10 min at 180Ug to obtain platelet-rich
plasma. Iloprost (100 nM) and apyrase (50 mg/l) were added and the
platelet-rich plasma centrifuged at 1000Ug for another 10 min. The
pellet was resuspended in Tyrode solution without Ca2 (‘Tyrode
bu¡er’: 138 mM NaCl, 2.7 mM KCl, 12 mM NaHCO3, 0.4 mM
NaH2PO4, 2 mM MgCl2, 5 mM glucose, PGI2 (20 ng/ml) and apyrase
(50 mg/l), pH 6.2) and washed twice with the same solution. After the
last centrifugation, the platelets were resuspended in a modi¢ed Ty-
rode bu¡er containing Ca2 (‘Tyrode-Ca2’ : 138 mM NaCl, 2.7 mM
KCl, 12 mM NaHCO3, 0.4 mM NaH2PO4, 2 mM MgCl2, 2 mM
CaCl2, 5 mM glucose, 5 mM HEPES, pH 7.35). The platelet suspen-
sion was kept at room temperature for 30 min before the start of the
incubations with lipoproteins and/or substances.
2.3. Determination of 125I-LDL binding to the platelets
LDL was isolated from plasma of healthy donors by sequential
£otation at 100 000Ug in the density range (d) = 1.019^1.063 and
was washed by £otation through KBr solution at d = 1.063 g/ml
[14]. Subsequently, the particles were ¢ltered (0.45 Wm). No contam-
inating plasma proteins were detected by immunoelectrophoresis. No
signs of oxidation were detectable with the thiobarbituric acid reactive
substance assay. Removal of KBr and rebu¡ering was performed by
size-exclusion chromatography with Sephadex G-25 immediately prior
to use. Radiolabeling was performed by means of N-chloro-benzene-
sulfonamide-conjugated polystyrene beads (Iodo Bead) following the
manufacturer’s instructions (Pierce, Rockford, IL, USA). The speci¢c
radioactivities of the 125I-LDL ranged from 100 to 300 cpm/ng pro-
tein.
Usually, the washed platelets were incubated with 125I-LDL at
room temperature for 30 min. After centrifugation through 20% aque-
ous sucrose in an Eppendorf centrifuge, the supernatant was removed
and the infranatant containing the platelets washed once with the
Tyrode bu¡er. The radioactivities of both the bound and unbound
fractions were determined. Unspeci¢c binding was determined as
platelet-associated radioactivity in the presence of a 50-fold excess
of unlabeled LDL.
2.4. Enrichment of LDL with pyrene-labeled phospholipids
Pyrene (py)-labeled phospholipids were incorporated into lipopro-
teins essentially as described previously [7]. Brie£y, 1 Wmol of either
py-SM, py-PC or py-PE were dissolved together with 3 Wmol of egg
PC in 20 Wl of ethanol. The phospholipids were directly added to 3 ml
of human plasma at 37‡C under argon by very slow injection with
gentle stirring. 0.74 mM diethyl-p-nitrophenylphosphate (DPNP) and
3 mM NaN3 were added and the suspension incubated for 24 h at
37‡C under argon. Pyrene-labeled lipoproteins were isolated by ultra-
centrifugation at 4‡C [14]. Low density lipoproteins were recovered at
a density range (g/ml) between 1.019 and 1.063.
Before starting the incubations with platelets, the lipoproteins were
extensively dialyzed at 4‡C under argon against a bu¡er containing
10 mM Tris-HCl, 150 mM NaCl, 0.3 mM EDTA (pH 7.4). The
protein contents of the labeled lipoproteins were determined [15].
Pyrene-labeled lipoproteins thus obtained migrated at the same dis-
tance as native lipoproteins as evidenced by agarose gel electropho-
resis. Lipids from LDL labeled with pyrene-containing phospholipids
were extracted [16] and phospholipids separated by one-dimensional
thin layer chromatography using the solvent chloroform/methanol/
acetic acid/H2O (90:40:12:2; v/v). The plates were viewed under
UV light. Fluorescence was detected exclusively in the phospholipid
fraction originally labeled in the vesicles.
2.5. Incorporation of 14C-phospholipids into LDL
14C-SM and 14C-PC were incorporated into LDL particles by pre-
paring egg PC vesicles with the 14C-phospholipids and subsequent
incubation of the vesicles with fresh plasma for 24 h at 37‡C under
argon [7]. 14C-labeled LDL was isolated by ultracentrifugation at 4‡C
[14]. The speci¢c activities thus obtained were 1.8^4.2U103 cpm/nmol
of the respective LDL-associated phospholipids. Before the start of
incubations with platelets, the lipoproteins were extensively dialyzed
at 4‡C under argon against a bu¡er containing 10 mM Tris-HCl, 150
mM NaCl, 0.3 mM EDTA (pH 7.4). 14C-Labeled lipoproteins mi-
grated at the same distance as the native lipoproteins as determined
by agarose gel electrophoresis.
2.6. Incubation of platelets with labeled lipoproteins and vesicles
Washed platelets were suspended with either pyrene-labeled LDL,
vesicle suspensions containing pyrene phospholipids, 125I-apolipopro-
tein B (apo B)-LDL or 14C-labeled LDL in Tyrode-Ca2 bu¡er at
either 37‡C or room temperature. After the incubation, labeled lip-
oproteins were removed by centrifugation and one washing step. In
the case of pyrene-labeled donors, the £uorescence was monitored
directly in the suspensions every 60 s (on line conditions). In some
cases, following incubation of platelets with pyrene-labeled donors,
£uorescence intensities were also determined after separation of do-
nors and acceptors by centrifugation (o¡-line experiments). Monomer
and excimer £uorescence of the suspensions were determined at emis-
sion wavelengths of 380 nm and 480 nm, respectively, with excitation
at 340 nm (excitation and emission slits of 5 and 10 nm). Incorpora-
tion of pyrene-labeled phospholipids into the platelets was followed
by the increase in monomer intensity after addition of platelets to the
donors. Fluorescence measurements were carried out using a Shimad-
zu RF-5001-PC spectro£uorometer (Shimadzu Germany, Duisburg).
All mean values are given þ S.E.M.
3. Results and discussion
Binding of LDL to the platelet surface was estimated by
incubating washed platelets (1.3U108) with two di¡erent con-
centrations of 125I-LDL (2 or 8 Wg/ml) at room temperature.
Under these conditions, the majority of 125I-LDL binding is
speci¢c as 81% of the platelet-associated 125I could be re-
moved by an excess of unlabeled LDL (Fig. 1). The e¡ect
of a polyclonal anti-GPIIb/IIIa antibody on platelet 125I-
LDL binding was evaluated. The lower concentration of the
antibody (47 Wg/ml) reduced 125I-LDL binding by 56% (2 Wg/
ml) and 49% (8 Wg/ml). Doubling the amount of the antibody
diminished binding of 125I-LDL to the platelets by 81% and
78% at the two concentrations of LDL (Fig. 1). Addition of a
non-immune IgG barely in£uenced the interaction of 125I-
LDL with the platelets.
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Fig. 1. Inhibition of 125I-LDL binding to platelets by an antibody
against GPIIb/GPIIIa. The indicated amounts of the anti-GPIIb/
IIIa antibody were given to the platelet suspensions (1.3U108) and
thereafter 125I-LDL was added either at 2 Wg protein/ml (empty col-
umns) or 8 Wg/ml (¢lled columns) for a total of 30 min (room tem-
perature). Aliquots without addition of the antibody were run in
parallel to determine the control binding. Non-speci¢c binding was
determined in the presence of a 50-fold excess of unlabeled LDL.
Mean values obtained on platelets from three di¡erent donors.
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In our search for modulators of LDL binding to platelets,
several substances were tested. Dextran sulfate (DS; 27 Wg/ml)
was found to enhance binding of 125I-LDL to platelets by 1.6-
fold (2 Wg/ml) and 2.8-fold (8 Wg/ml LDL protein) (Fig. 2).
The increased binding of the lipoprotein to the platelets elic-
ited by DS nearly entirely represented speci¢c binding since it
could be removed by an excess of unlabeled LDL (Fig. 2).
The screening for modulators of LDL binding furthermore
revealed that wheat germ agglutinin (WGA, 20 Wg/ml) low-
ered total binding of 125I-LDL to the platelets by 75^86%
(Fig. 2). WGA decreased binding of 125I-LDL to the platelets
to a similar extent as the excess of unlabeled LDL. At the
concentration of WGA applied, no platelet aggregation was
found as analyzed using an aggregometer.
On the basis of these results we evaluated whether the mod-
ulations of platelet 125I-LDL binding exerted by the antibod-
ies, WGA and DS, a¡ected platelet phospholipid import.
LDL particles were labeled with py-SM, py-PC or py-PE
and incubated with the platelets at 37‡C. The platelets rapidly
acquired py-SM and py-PC from the donor lipoproteins with-
in 5 min (Fig. 3A, upper and lower panels). Addition of the
two concentrations of the anti-GPIIb/IIIa antibody neither
altered import of py-SM nor a¡ected uptake of py-PC. The
incorporation of py-PE into the platelets as determined after a
3 min incubation of py-PE-labeled LDL (2 Wg/ml) with the
platelets at 37‡C was not changed by the presence of the anti-
GPIIb/IIIa antibody (94 Wg/ml) (1.2 þ 0.4 (control) vs.
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Table 1
E¡ect of WGA on platelet-associated 14C following incubation of
platelets with 14C-phospholipid LDL
Platelet-associated 14C
(cpm/108 platelets)
14C-SM 14C-PC
Control 405 þ 30 310 þ 40
+unlabeled LDL 185 þ 20 140 þ 25
WGA 1050 þ 70 360 þ 30
+unlabeled LDL 610 þ 80 155 þ 35
Platelets (1U108) were incubated for 5 min at 37‡C with LDL (15 Wg/
ml, containing either 14C-SM or 14C-PC) in the absence or presence of
WGA (20 Wg/ml). 14C-Lipoproteins were removed by centrifugation
and one washing step. In some cases the suspensions were subse-
quently incubated for 40 min with a 40-fold excess of unlabeled
LDL. Mean values from a total of four determinations on platelets
from two donors.
Fig. 3. E¡ects of the anti-GPIIb/IIIa antibody, WGA and DS on transfer of py-phospholipids from LDL to platelets. Platelet suspensions
(1.3U108) were incubated with 2 Wg/ml LDL (containing either py-SM or py-PC (30^36 ng pyrene)) in the absence or presence of the anti-
GPIIb/IIIa antibody, WGA (20 Wg/ml) or DS (27 Wg/ml) at 37‡C. A: a, control; 8, 47 Wg/ml of antibody; b, 94 Wg/ml of antibody. B: a,
control; F, WGA; R, DS. The platelet uptake of the py-phospholipids was estimated from the increase in monomer £uorescence under on-line
conditions. Mean values on platelets from 4^6 di¡erent donors.
Fig. 2. In£uences of WGA and DS on platelet binding of 125I-LDL.
Platelet suspensions (1.5U108) were incubated for 30 min at room
temperature with either 2 Wg/ml (empty columns) or 8 Wg/ml
125I-LDL (¢lled columns) in the absence or presence of WGA
(20 Wg/ml) or DS (27 Wg/ml). Mean values on platelets of three dif-
ferent donors.
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1.1 þ 0.3 ng pyrene/1.3U108 platelets (+antibody); means of
four experiments). In addition, at the LDL concentration of
8 Wg protein/ml, the transfer of py-SM, py-PC and py-PE was
also una¡ected by the anti-GPIIb/IIIa antibody (94 Wg/ml)
(data not shown). Following a 3 min incubation with py-
SM-labeled LDL (2 Wg/ml, containing 33 ng py-SM) at
room temperature, the amount of labeled phospholipid incor-
porated int the platelets was not altered by the anti-GPIIb/
IIIa antibody (94 Wg/ml; 1.3 þ 0.3 (control) vs. 1.4 þ 0.3 ng py/
1.2U108 platelets (+antibody); means of three experiments).
In further experiments, the in£uence of DS and WGA on
the platelet uptake of py-labeled choline phospholipids was
tested (Fig. 3B). The transfer of py-SM and py-PC from
LDL to the platelets was not a¡ected by DS (27 Wg/ml). In
contrast, WGA (20 Wg/ml) time-dependently increased the im-
port of py-SM into platelets. After 3 and 5 min of incubation,
the incorporation of py-SM was stimulated by 2.7- and 2.9-
fold at 37‡C. The incorporation of py-PC (Fig. 3B) and of py-
PE (not shown) was una¡ected by WGA. The e¡ect of WGA
(20 Wg/ml) on the transfer of py-SM from LDL (2 Wg/ml; 33
ng py-SM) to the platelets was also determined at room tem-
perature. Under these conditions, the lectin stimulated platelet
py-SM uptake by 2.8-fold within 3 min (from 1.4 þ 0.2 (con-
trol) to 3.9 þ 0.5 ng py/1.3U108 platelets (+WGA); means of
three experiments).
In order to determine whether WGA a¡ected the transfer of
14C-phospholipids from LDL to the platelets, platelets were
incubated with LDL (15 Wg/ml, containing either 14C-SM or
14C-PC) in the absence or presence of WGA (20 Wg/ml) at
37‡C. Thereafter, the amount of platelet-associated 14C was
determined. In platelets treated with WGA, the quantity of
platelet 14C-SM was 2.6-fold higher compared to the unstimu-
lated platelets (Table 1). After removal of platelet bound 14C-
LDL by unlabeled LDL, the amount or platelet 14C was 3.3-
fold higher in the WGA-treated platelets. Following incuba-
tion of platelets with 14C-PC-LDL in the presence of WGA,
the quantity of platelet 14C was similar to the amount deter-
mined after incubation of untreated platelets with 14C-PC-
LDL. This was also evident in platelets subsequently incu-
bated with unlabeled LDL (Table 1). Taken together, the
data indicate that 125I-LDL binding and phospholipid transfer
between lipoproteins and platelets are di¡erentially a¡ected by
the anti-GPIIb/IIIa antibody, DS and WGA.
Also the concentration dependences of both processes argue
against a decisive role of speci¢c LDL binding for the phos-
pholipid uptake process. Speci¢c binding of 125I-LDL to the
platelets is half maximal at about 0.01 mg LDL protein/ml
[13]. On the other hand, the half-maximal transfer of LDL
derived 14C-SM and 14C-PC into the platelets is observed at
about 0.5 mg LDL protein/ml [8]. We conclude from these
data that phospholipid transfer from LDL to platelets is
largely independent of the high a⁄nity 125I-LDL binding to
the platelets. Therefore, the residual (low a⁄nity) interaction
of the particles with the platelets is expected to be involved in
the phospholipid transfer. The extracellular surfaces of di¡er-
ent cell types were previously reported to possess receptors for
speci¢c phospholipids, in particular for phosphatidylserine
[17,18].
Speci¢c binding of LDL to the platelets may involve pro-
tein-protein interactions between the LDL associated apo B-
100 and the platelet GPIIb/IIIa complex [19]. In order to
evaluate whether the apoprotein component of LDL was nec-
essary for platelet phospholipid import, we investigated
whether the platelets incorporated phospholipids from pure
phospholipid vesicles. During incubation of platelets with lip-
id vesicles containing py-labeled phospholipids, a time-de-
pendent increase in pyrene monomer £uorescence was ob-
served for the three types of phospholipids analyzed (Fig.
4). This was accompanied by a decrease in excimer/monomer
ratios. The amount of py-SM taken up within a 10 min in-
cubation interval was similar to the quantity of py-PC incor-
porated by the platelets (Fig. 4). The transfer of py-PE was
lower compared to the one of py-labeled choline phospholip-
ids. These results indicate that lipid vesicles can serve as do-
nors for phospholipid transfer into the platelets. The import
of the lipoprotein-derived choline phospholipids PC and SM
into the platelets is reduced after preincubation of platelets
with elastase [7]. In platelets pretreated with the protease,
the transfer of py-SM from vesicles to platelets was dimin-
ished by 44% (Fig. 4). The import of py-PC was lowered by
41%, while the incorporation of vesicle-derived py-PE was not
altered by elastase pretreatment.
Next, we evaluated whether WGA a¡ected the transfer of
py-phospholipids from lipid vesicles to platelets. Within a
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Fig. 4. Inhibition of py-phospholipid transfer from lipid vesicles to
platelets by elastase. Platelets (1U108) were pretreated for 10 min
with elastase (9 U/ml), proteolysis stopped by a 5-fold amount of
K1-antitrypsin and egg PC vesicles added for a further 10 min at
37‡C. The vesicles contained 31 Wg egg PC and 0.6 Wg of py-phos-
pholipids. The platelet uptake of the py-phospholipids was estimated
from the increase in monomer £uorescence under on-line conditions.
a, control; F, elastase-pretreated platelets. Data are shown from
one representative of a total of three experiments.
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5 min incubation interval, WGA (20 Wg/ml) stimulated the
import of py-SM by 5.3-fold (Table 2). The platelet uptake
of py-PC was not altered in the presence of the lectin. WGA
may exert its stimulatory e¡ect on platelet phospholipid im-
port by speci¢cally binding to N-acetylglucosamine residues
(present on platelet cell membrane proteins or lipids) or by
unspeci¢c interactions. When adding the monosaccharide
alone to the platelet suspension, the transfer of py-SM from
the vesicles to the platelets was not altered. On the other
hand, N-acetylglucosamine completely prevented the stimula-
tion of py-SM import induced by WGA (Table 2). This sug-
gests that the enhanced incorporation of SM into WGA-
treated platelets is mediated by a speci¢c interaction of the
lectin with N-acetylglucosamine residues on the platelet sur-
face.
On the basis of these data it is evident that the transfer of
phospholipids from either LDL or lipid vesicles into the plate-
lets shares several common characteristics. Firstly, py-PC and
py-SM were incorporated faster as compared to py-PE (Figs.
3 and 4). Secondly, protease pretreatment of the platelets
reduced the import of py-labeled PC and SM but did not
in£uence the uptake of py-PE (Fig. 4 and [7]). Thirdly,
WGA stimulated uptake of SM into the platelets from LDL
and the vesicles without a¡ecting the incorporation of PC and
PE (Fig. 3, Tables 1 and 2). Thus, the characteristics of phos-
pholipid import into the platelets are independent of the apo-
protein component of LDL.
WGA is known to induce platelet activation [20,21], the
e¡ect being in part due to the stimulation of tyrosine and
other protein kinases [22,23]. The platelet stimulation elicited
by WGA di¡ers from that induced by thrombin and other
platelet agonists [24]. In line with this observation, thrombin,
collagen and ADP ^ while accelerating uptake of ethanol-
amine phospholipids ^ did not increase the incorporation of
py-SM into the platelets [9]. Together, these data strongly
suggest that di¡erent routes exist for the import of phospho-
lipids into the platelets which are speci¢cally activated accord-
ing to the type of platelet agonist present.
LDL particles deliver phospholipid-bound arachidonic acid
to the platelets which, in turn, can be further metabolized to
autocrine and paracrine eicosanoids. This supply markedly
depends on the LDL concentration, an increase being ob-
served in the physiological and pathological range of lipopro-
tein concentrations [8]. Within a comparable concentration
range, low a⁄nity LDL binding sites on the platelet surface
have been described earlier [25]. Several of the multiple in£u-
ences of LDL on the functional responses of platelets (sum-
marized in [26]) require LDL concentrations at or above the
upper physiological range. It is conceivable, therefore, that
some of these e¡ects may be related to changes in phospho-
lipid import. In future studies on platelet LDL interactions,
the rapid import of phospholipids should be considered a
potential mediator of LDL e¡ects on platelet function.
In conclusion, selective phospholipid import pathways are
stimulated by di¡erent types of platelet activation. The data
suggest that apart from the previously described high a⁄nity
binding of LDL to the platelets there is a low a⁄nity inter-
action between the two compartments which mediates the
supply of phospholipids to the platelets.
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Table 2
E¡ect of WGA on transfer of py-labeled phospholipids from lipid
vesicles to the platelets
Platelet import of py-phospholipids
(ng pyrene/108 platelets)
py-SM
no addition 10.6 þ 2.5
N-acetylglucosamine 9.4 þ 1.8
WGA 56.0 þ 11.1
WGA+N-acetylglucosamine 9.7 þ 3.2
py-PC
no addition 9.8 þ 2.9
WGA 10.3 þ 2.5
Platelets (1U108) were incubated for 5 min at 37‡C with egg PC
vesicles containing either py-SM or py-PC under the same conditions
as detailed in legend to Fig. 4. N-acetylglucosamine (5 mM) and/or
WGA (20 Wg/ml) were given to the platelet suspension immediately
before addition of the vesicles. Mean values on platelets from 3^5
di¡erent donors.
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